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Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell-based disorders
characterized by ineffective hematopoiesis, increased genomic instability and a tendency
to progress toward acute myeloid leukemia (AML). MDS and AML cells present genetic
and epigenetic abnormalities and, due to the heterogeneity of thesemolecular alterations,
the current treatment options remain unsatisfactory. Hypomethylating agents (HMA),
especially azacitidine, are the mainstay of treatment for high-risk MDS patients and HMA
are used in treating elderly AML. The aim of this study was to investigate the potential
role of the epigenetic reader bromodomain-containing protein-4 (BRD4) in MDS and
AML patients. We identified the upregulation of the short variant BRD4 in MDS and
AML patients, which was associated with a worse outcome of MDS. Furthermore, the
inhibition of BRD4 in vitro with JQ1 or shRNA induced leukemia cell apoptosis, especially
when combined to azacitidine, and triggered the activation of the DNA damage response
pathway. JQ1 and AZD6738 (a specific ATR inhibitor) also synergized to induce apoptosis
in leukemia cells. Our results indicate that the BRD4-dependent transcriptional program
is a defective pathway in MDS and AML pathogenesis and its inhibition induces apoptosis
of leukemia cells, which is enhanced in combination with HMA or an ATR inhibitor.
Keywords: myelodysplastic syndromes, acute myeloid leukemia, BET member of bromodomain-containing
proteins, azacitidine, AZD6738
INTRODUCTION
Myelodysplastic syndromes (MDS) encompass a heterogeneous group of disorders characterized
by molecular alterations in hematopoietic stem cells, leading to ineffective hematopoiesis and risk
of acute leukemia. Progression to acutemyeloid leukemia (AML) occurs in one third of the patients,
and it is believed to be the result of increased genomic instability (1). The disease predominantly
affects older patients, with a median age of around 70 years and annual incidence in the range
of 4–8 cases/100,000 individuals (2). Elderly AML (>65 years) presents a median survival of
just 5–6 months (3). MDS and AML cells exhibit aberrant methylation in promoter regions of
tumor-suppressor genes, which has been tracked to the most immature cells (4, 5) and is associated
to gene mutations involving epigenetic modifiers (6, 7). Increased DNA damage and alterations
in the DNA damage response pathway (DDR) are critical features of gene instability that are
implicated in the pathogenesis of MDS and AML (8).
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Hypomethylating agents (HMA), especially azacitidine, are
the current mainstay for the treatment of advanced MDS
and elderly AML, inducing hematological improvement, partial
and complete responses, resulting in long-term survival (3, 9).
However, hematological improvement occurs in only 30% of
patients on HMA therapy (10). Therefore, drug combinations
aiming to increase HMA efficiency are needed. Bromodomain
containing proteins (BET proteins) are the most prominent
group of epigenetic reader proteins, recognizing and binding
to acetylated lysine residues within histone tails. BET proteins
influence gene expression, cell-cycle regulation and maintain
an association with chromatin throughout mitosis, facilitating
“gene bookmarking.” As a member of the BET family, BRD4
bromodomain containing 4 (BRD4) acts by inducing the
expression of growth-promoting genes and has been described
as a therapeutic target for AML (11). BRD4 generates two major
transcriptional variants: long and short. The C-terminal domain
of the long isoform of BRD4 has been described as crucial
for maintaining normal chromatin structure (12). Conversely,
BRD4 short variant function is less known. It has been shown
as an endogenous inhibitor of DDR signaling, recruiting the
condensing II chromatin remodeling complex to acetylated
histones (13).
Herein, we describe an increased expression of the short
variant of BRD4 in MDS and AML patients and establish
BRD4 short variant overexpression as a new independent MDS
prognostic factor. The combination of a BRD4 inhibitor (JQ1)
and the HMA, azacitidine, was more effective than azacitidine
or JQ1 alone for inducing cell apoptosis. JQ1 and AZD6738
(a specific ATR inhibitor) also synergized to induce apoptosis,
suggesting a role for the combination of BET inhibitors with
HMA or DDR inhibitors in MDS and AML treatment.
MATERIALS AND METHODS
Patient Samples
Bone marrow samples were collected from patients with MDS
(n = 58), AML with MDS-related changes AML (AML-MRC)
(n = 16), de novo AML (n = 34), and healthy donors (n =
24). All patients included in the study were untreated at the
time of sample collection. MDS patients were classified according
to 2016 World Health Organization (WHO) classification (14)
and according to revised international prognostic staging system
(R-IPSS) (15). The cytogenetic risk for MDS and AML was
defined according to R-IPSS (15) and to the Medical Research
Council cytogenetic classifications (16), respectively. Healthy
donors’ and patients’ characteristics are described in Table 1.
All healthy donors and patients signed informed consent forms
under a local research protocol. This study was approved by the
Institutional Ethical Review Board in accordance to the Helsinki
Declaration.
Abbreviations:MDS, myelodysplastic syndromes; AML, acute myeloid leukemia;
BET, bromodomain containing proteins; HMA, hypomethylating agents; BRD4,
Bromodomain-containing protein 4; AZA, azacitidine.
TABLE 1 | Characteristics of healthy donors and patients.
Number
HEALTHY DONORS
Gender (male/female) 17/7
Age (years), median (range) 36 (23–69)
PATIENTS
MDS 58
Gender (male/female) 34/24
Age (years), median (range) 64 (16–90)
WHO 2016 classification
MDS-RS/MDS-MLD (<5% BM blasts) 5/31
MDS-EB1/MDS-EB2 (≥5% BM blasts) 11/11
IPSS-R
Very low/low risk 7/24
Intermediate/high/very high risk 10/12/5
Cytogenetic riska
Very good/good 2/46
Intermediate 3
Poor/very poor 2/2
No growth 3
de novo AML 34
Gender (male/female) 18/16
Age (years), median (range) 55 (17–93)
BM blasts (%), median (range) 68 (28–98)
Cytogenetic riskb
Good 5
Intermediate/Poor 19/4
No growth 6
AML-MRC 16
Gender (Male/Female) 11/05
Age (years), median (range) 70 (36–81)
BM blasts (%), median (range)c 45 (11–75)
Cytogenetic riskd
Good 0
Intermediate/Poor 8/8
No growth 0
MDS, myelodysplastic syndromes; WHO, World Health Organization; MDS-RS, MDS
with ringed sideroblasts; MDS-MLD, MDS with multilineage displasia; MDS-EB1, MDS
with excess blast-1; MDS-EB2, MDS with excess blast-2; IPSS-R, revised International
Prognostic Scoring System; AML, acute myeloid leukemia; BM, bonemarrow; AML-MRC,
acute myeloid leukemia with myelodysplastic related changes.
a In MDS cohort, karyotype findings included very good risk: -Y (n = 1), del(11q) (n = 1);
good risk: normal (n = 46); intermediate: inv(9) and del(16q22) (n = 1), rob(14;14) (n = 1),
inv(9) (n = 1); poor: −7 (n = 2); very poor: >3 abnormalities (n = 2).
b In AML cohort, karyotype findings included good risk: t(8;21) (n = 4), inv(16) (n = 1);
intermediate risk: normal (n = 16), trisomy 8 (n = 1), and other abnormalities (n = 2);
poor risk included complex karyotype (n = 2), del(5q) (n = 1), and others (n = 1).
cBM blasts percentage included 2 patients with lower than 20% blasts due to acute
erythroid leukemia.
d In AML-MRC cohort, karyotype findings included intermediate risk: trisomy 8 (n = 2),
normal (n = 4), and other abnormalities (n = 2); poor risk included complex karyotype
(n = 5), del(5q) (n = 1), monosomy 7 (n = 2).
CD34+ Cell Separation
Bone marrow mononuclear cells were isolated by Ficoll-Paque
(GE, Uppsala, Sweden) from diagnostic samples of AML
patients and cord blood units (CBU) samples from full-term
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deliveries. After that, primary human CD34+ hematopoietic
stem and progenitor cells (CD34+ cells) were selected using
immunomagnetic activated cell sorting columns (Miltenyi
Biotech, Auburn, CA, USA), obtaining purity of at least 90%.
Cell Culture
A panel of humanmyeloid leukemia cell lines (HEL, HL60, K562,
and U937) was cultured in Roswell Park Memorial Institute
medium-1640 (RPMI) (Sigma) containing 10% FBS, glutamine
(2mM), penicillin (100µg/mL), streptomycin (100µg/mL), and
amphotericin B (0.25µg/mL). The cells were maintained in a
humidified atmosphere at 37◦C and 5%CO2 and the experiments
were performed when they reached exponential growth.
Chemical Reagents
A BRD4 specific inhibitor (JQ1) was kindly provided by
Dr. James Bradner (Dana-Farber Cancer Institute, Harvard
Medical School, Boston, MA). The compound was diluted in
dimethylsulfoxide (DMSO) to a 10mM stock solution and
was added to the cells at final concentrations of 0.24µM to
100µM for 48 h. Azacitidine (AZA) was also diluted in DMSO
to a 100mM stock concentration and added to cells at final
concentrations of 1–3µMfor 48 h. The AZA concentration range
was chosen based on the established AZA treatment schedule for
MDS patients (75 mg/m2/day), which achieved plasma levels in
the range of 3–11µM (17, 18). The dose of 1µM was used for
both drugs when JQ1 and azacitidine were combined. AZD6738
was obtained from Selleck Chemicals (Houston, TX) diluted
in DMSO and added to the cells at final concentrations of 1–
20µM. GI30 (drug inhibition of 30%) was determined after 48 h
of exposure and used in combination with 1µM of JQ1 or
azacitidine.
Gene Expression Analysis
RNA was extracted using the RNeasy Plus Micro Kit (Qiagen,
Valencia, CA, USA) and reversely transcribed into cDNA with
the RevertAid H Minus First Strand cDNA Synthesis Kit (MBI
Fermentas, St. Leon-Rot, Germany). The quantitative RT-PCR
(qRT-PCR) reaction was run with SYBR Green Master Mix PCR
(Fermentas) using the ABI 7500 Sequence Detection System
(Applied-Biosystem, Foster City, CA, USA). The values of the
relative quantification of gene expression was calculated through
the equation 2−11CT (19). A negative no “template control” was
included for each primer pair and the amplification specificity
was verified using a dissociation curve at the end of each run.
Three replicas were run on the same plate for each sample. Sense
and antisense primers were designed to be complementary to the
sequences contained in different exons. The following primers
were used: BRD4 long variant (BRD4L), 5′- AAAGGACCTGAA
AATCAAGAACATG-3′ and 5′-GAAGCTGTCGCTGGAT
GACTT-3′; BRD4 short variant (BRD4S) 5′-CTGACAGCGAAG
ACTCCGAAA-3′ and 5′-GCTATAGCTTGCTGGGAAGGAA-
3′, hypoxanthine phosphoribosyltransferase (HPRT), 5′-GAAC
GTCTTGCTCGAGATGTGA-3′ and 5′-TCCAGCAGGTCA
GCAAAGAAT-3′.
Western Blotting
Equal amounts of protein were submitted to electrophoresis
on SDS polyacrylamide gels under reducing conditions and the
nitrocellulose membrane was blotted with specific antibodies.
Polyclonal antibodies against cleaved PARP-1 (sc-56196), CDK6
(sc-56282), GAPDH (sc-32233), and ACTIN (sc-1616) were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-phospho-histone H2AX (Ser139) (pH2AX) (9718),
P53 (2524), and anti-caspase 3 (9665) were purchased from
Cell signaling (Danvers, MA, USA) and P21 were obtained
from Abcam (Cambridge, MA, USA). The target proteins were
analyzed by chemiluminescence using an ECL Plus Kit (GE-
Healthcare, Buckinghamshire, England). Quantitative analyses of
the optical intensities of protein bands were determined with
UN-SCAN-IT graph digitalizing software (Silk scientific, UT,
USA) and normalized by actin or GAPDH for protein expression.
Assessment of Cell Growth
Cell growth was measured by methylthiazoletetrazolium (MTT)
assay. Briefly, 2.5 × 104 cells per well were plated in 96–well
plates in RPMI/10% FBS for 48 h. MTT solution (5 mg/mL) was
added to each well and incubated at 37◦C for 4 h. The reaction
was stopped by 0.1N HCl in anhydrous isopropanol. Cell growth
was evaluated by measuring the absorbance at 570 nm, using an
automated plate reader (Multiscan MS, Labsystems).
Assessment of Apoptosis
Cell death was measured by annexin-V and PI assay. Briefly,
the cells were seeded in 24-well plates and treated or not with
different concentrations of JQ1 and/or azacitidine for 48 h. After
this period, the cells were collected and incubated with 1µg/mL
propidium iodide (PI) and 1µg/mL APC-Annexin-V for 15min
at room temperature in the dark. All specimens were analyzed
on a FACSCalibur (BD Biosciences, CA, USA) and 10,000 events
were acquired for each sample.
Transduction With Lentivirus
U937 cells were transduced with lentivirus-mediated shRNA
non-specific control (sc-108080) or lentivirus-mediated shRNA
targeting BRD4 (sc-43639-V) from Santa Cruz Biotechnology
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and named
shControl and shBRD4 cells, respectively. Pooling of multiple
BRD4 shRNAs (three different sequences) was used to reduce
possible off-target effects of the shRNAs. BA/F3 cells were
transduced with lentivirus particles produced using pCDH-MSV-
MCS-EF1α empty vector (control) or containing the full lengths
of BRD4S or BRD4L. Briefly, 2 × 105 cells were transduced with
lentivirus by spinoculation at multiplicity of infection (MOI)
equal to 1 and selected with specific antibiotics for at least 7
days before using in the experiments. BA/F3 cells were also
sorted using a FACsAria Fusion (Becton–Dickinson Biosciences)
in addition to antibiotic selection.
Cell Cycle Analysis
Cells were seeded on a 24-well plate and treated or not with
different concentrations of JQ1 for 48 h. Next, the cells were
collected and fixed overnight in 70% ethanol. DNA was stained
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with Pipes buffer containing PI (20µg/mL) and RNase A
(10µg/mL). Cell fluorescence was detected with a FACSCalibur.
The proportions of cells in the cell cycle phases were analyzed
by Modifit (Verify Software House Inc., Topsham, ME, USA),
according to DNA distributions.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism5
software (GraphPad Software, Inc., San Diego, CA, USA) or SAS
System for Windons 9.2 (SAS Institute, Inc., Cary, NC, USA).
Data were expressed as the median [minimum-maximum]. For
comparisons, an appropriate Mann–Whitney test, Student’s t-
test or ANOVA was used. Comparison between patient groups
was performed by analysis of t-test and covariance (ANCOVA)
controlled for age, followed by post-hoc comparisons using
the Tukey test. All experiments were repeated at least four
times. Cox regression model was used to estimate overall
survival (OS) and event-free survival (EFS) for MDS patients.
The stepwise process of selection was used for multivariate
analysis. OS was defined as the time (in months) between
the date of sampling and the date of death (for deceased
patients) or last follow-up (for censored patients). EFS was
defined as the time (in months) between the date of sampling
and the first event (death or MDS progression or leukemic
transformation) or last follow-up (for censored patients). All
tests were two-tailed. P ≤ 0.05 were considered statistically
significant.
RESULTS
BRD4 Short Variant Expression Is
Increased in Total Bone Marrow Cells From
MDS and AML Patients and Associates
With Worse Outcomes in MDS
The first step of this study comprised the evaluation of mRNA
levels of both BRD4 variants in total bone marrow cells from
healthy donors (n = 24), MDS (n = 58), and AML (n = 50)
patients. In order to exclude confounders, we carried out an
ANCOVA analysis, which showed that age and gender did not
interfere in our results.
BRD4S expression was significantly increased in both MDS
(4.21 [0.01–56.17]) and AML (4.01 [0.33–26.58]) patients, when
compared to healthy donors (2.11 [0.04–10.32]; all P < 0.01)
(Figure 1A). No difference in BRD4L expression was observed
between healthy donors, MDS and AML patients (Figure 1B).
There were no differences when MDS patients were stratified
according BM blasts or when AML patients were grouped into
de novo AML or AML with myelodysplasia related changes
(AML-MRC).
With a median follow-up time of 34.4 months, BRD4S
expression appeared as one of the variables with significant
impact in event-free survival (EFS) and overall survival (OS)
of MDS patients in univariate analysis. The bone marrow blast
percentages (absolute values) and R-IPSS (stratified into very
low/low, intermediate and high/very high) also significantly
FIGURE 1 | BRD4 short variant gene is overexpressed in MDS and AML patients. BRD4S mRNA expression in total bone marrow cells from healthy donors, MDS
<5% BM blasts, >5% BM blasts, AML-MRC and de novo AML patients (A); BRD4L mRNA expression in total bone marrow cells from healthy donors, MDS <5% BM
blasts, >5% BM blasts, AML-MRC, and de novo AML patients (B); Efficiency of GFP-positive BA/F3 cells transduced with empty vector, BRD4S and BRD4L, in that
order, measured by flow cytometry (C) and by quantitative PCR (D); (E) Comparative growth (normalized by the initial number of cells) of BA/F3 parental cells (with
and without IL-3), control (empty vector) or transduced with full-length BRD4S or BRD4L. The number of subjects and significant P-values (Mann–Whitney test) are
indicated in the graph. MDS, myelodysplastic syndromes; AML, acute myeloid leukemia; AML-MRC, acute myeloid leukemia with myelodysplastic related changes.
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altered EFS and OS. Multivariate analysis demonstrated that
higher BRD4S expression, along with intermediate and high/very
high R-IPSS risk MDS, were the only independent factors related
to worse outcomes (Table 2).
Aiming to explore a possible function of BRD4 as an
oncogene, we overexpressed BRD4L or BRD4S using GFP
tagged in normal hematopoietic murine cells (BA/F3), which
are dependent on IL-3, and accessed daily the cell growth
for 144 h in the presence or absence of 20 ηg/mL IL-3. The
overexpression of both variants was effective (Figures 1C,D),
but overexpression of BRD4L or BRD4S did not lead to IL-3
independency (Figure 1E). In the presence of IL-3, the growth
of BRD4S or BRD4L overexpressed cells were also similar to the
control (data not shown). These results suggest that BRD4 does
not act as an oncogene alone.
JQ1 Treatment Reduces Cell Viability,
Along With the Induction of Apoptosis and
G0/G1 Cell Cycle Arrest in Myeloid
Leukemia Cell Lines, but Not in Normal
CD34+ Cells
In order to characterize the role of BRD4 in the disease
pathogenesis, a panel of myeloid leukemia cell lines was treated
with JQ1, an inhibitor of both BRD4 isoforms and other BET
protein members (20, 21). Treatment with JQ1 induced a dose-
dependent reduction in cell viability, in association with a
similar induction of apoptosis. U937 and K562 cells were more
resistant to the treatment, and presented higher GI50 (growth
inhibitory concentration, with 50% reduction in cell viability)
levels compared with HL60 and HEL cells (Figure 2A). Normal
CD34+ cells from four samples of cord blood units exhibited
greater tolerability to JQ1, with sustained cell viability and
lower apoptosis rate compared to neoplastic cells (Figure 2B).
JQ1 treatment induced an increase in G0/G1 cell cycle in cell
lines, indicating cell cycle arrest (Figure 2C). We also observed
an increase in p-H2AX in both HEL (more sensitive) and
U937 (more resistant) cell lines, along with decreasing levels
of CDK6 and with higher P53 and P21 protein concentrations
(Figure 2D). This result suggests that BRD4 pharmacological
inhibition causes DDR pathway activation and cell cycle arrest,
even when the cells were exposed to a lower dose of JQ1.
JQ1 Exhibits an Additive Effect Together
With Azacitidine on the Apoptosis of
Leukemia Cell Lines and CD34+ AML
Primary Cells
With the aim of further characterizing the potential combinatory
effects of BRD4 inhibition and a standard treatment for MDS,
HEL, and U937 cells were treated with JQ1 and azacitidine
for 48 h. JQ1 + AZA treatment increased the apoptotic rate
of both cell lines, particularly in U937 cells (Figure 3A). JQ1
treatment increased p-H2AX and cleaved PARP-1, suggesting
that activation of DDR is an important mechanism for apoptotic
induction after JQ1 treatment. Although annexin V positive
cells were increased with the co-treatment, we did not observe
the same synergism in pH2AX and cleaved PARP-1 expression,
possibly because high levels of these proteins were already
detected when JQ1 was used alone (Figure 3B). CD34+ cells were
isolated from diagnostic samples of 5 AML patients and treated
with JQ1, AZA or both. In all samples, the combination of JQ1
and AZA induced a higher apoptosis rate than JQ1 or AZA alone
(Figure 3C).
BRD4 Silencing Decreases Proliferation
and Apoptosis and Potentiates the
Proapoptotic Effect of Azacitidine
We next sought to investigate whether BRD4 gene
silencing would produce similar results to that of JQ1
TABLE 2 | Univariate and multivariate analysis for event-free survival and overall survival of MDS patients.
Factor Univariate analysis Multivariate analysis
Event free survival Overall survival Event free survival Overall survival
HR 95% C.I. P HR 95% C.I. P HR 95% C.I. P HR 95% C.I. P
IPSS-R RISK GROUP
Intermediate vs. very
low/low
6.0 2.2–16.6 0.0006 6.9 2.4–20.0 0.0004 4.9 1.6–15 0.006 4.8 1.6–14.7 0.007
Very high/high vs. Very
low/low
8.9 3.4–22.7 <0.0001 12.4 4.6–33.6 <0.0001 9.7 3.4–27.8 <0.0001 12.3 4.2–35.7 <0.0001
BM BLAST PERCENTAGE
Absolute values 1.1 1.1–1.2 <0.0001 1.2 1.1–1.2 <0.0001
BRD4L EXPRESSION
Absolute values 1.2 0.8–1.8 0.34 1.2 0.8–1.8 0.75
BRD4S EXPRESSION
Absolute values 1.05 1.01–1.08 0.02 1.05 1.01–1.09 0.02 1.04 1.01–1.09 0.02 1.05 1.01–1.10 0.01
Statistically significant P-values are highlighted in bold; MDS, myelodysplastic syndromes; HR, hazard ratio; when HR > 1 indicates that the first factor has the poorer outcome; C.I,
confidence interval; BM, bone marrow; BM, blast percentage, BRD4L and BRD4S expression were analyzed as continuous numerical values.
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FIGURE 2 | JQ1, a BRD4 inhibitor, reduces cell viability, induces apoptosis and cell cycle arrest of leukemia cell lines, with variable drug sensitivity. (A) Cell viability and
apoptosis were determined by MTT assays and flow cytometry after 48 h of JQ1 treatment and growth inhibition (GI50) of four leukemia cell lines (HL60, HEL, K562,
and U937). GI50 values determined from at least five independent experiments, by non-linear curve fitting to a sigmoid dose-response model; (B) Treatment of CD34
+
cells from cord blood units (CBU) with increasing doses of JQ1 showed no significant cell viability reduction or apoptosis induction in that order; (C) Cell cycle phases
were detected by flow cytometry. The cell lines tested are indicated in the graph. Results are shown as the percentage of total cells and bars represent increasing
doses of JQ1. Graph bars represent a minimum of 6 independent experiments. (D) Western blotting analysis of total cell extracts from HEL, HL60, and U937 cells
after 48 h of treatment with JQ1. The membrane was blotted anti-pH2AX (15 kDa), P53 (53 kDa), CDK6 (36 kDa), P21 (18 kDa), and for GAPDH (37 kDa) or ACTIN (43
kDa) as a control for equal sample loading, and developed with the ECL Western Blotting Analysis System. Densitometry was performed and the ratio of p-H2AX vs.
GAPDH compared with the normalized value of control is shown. Western blot figures are representative of all experiments performed. All bar graphs represent mean
± SD of at least five independent experiments.
treatment, in order to exclude possible therapy-related
off target effects. For this purpose, U937 cells were stably
transduced with lentivirus-mediated shRNA targeting BRD4
(shBRD4) or an appropriate control (shControl) and the
efficacy of the transduction was confirmed by qRT-PCR
(Figure 4A).
Apoptosis was evaluated in silenced cells treated or not with
1 or 3µM AZA for 48 h. Following AZA treatment, shBRD4
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FIGURE 3 | Combined treatment of JQ1 and azacitidine induces an additive effect on apoptosis of HEL, U937, and primary AML cells.(A) Apoptosis rate of HEL and
U937 cell lines treated with JQ1, AZA, or JQ1+AZA for 48 h: Bar graphs show mean ± SD of at least four independent experiments. (B) Western blotting of HEL and
U937 cell lines extract showing increased p-H2AX and cleaved PARP expression after JQ1+AZA treatment. Densitometry was performed and the ratio of target
proteins vs. GAPDH compared with the normalized value of control is shown. (C) Apoptosis rate of 5 primary CD34+ AML cells treated with JQ1, AZA, and JQ1+AZA
and a representative plot showing increasing apoptosis under JQ1+AZA combination.
cells showed a significant increase in apoptotic rate (P <
0.05) (Figures 4B,C), similarly to that observed for the drug
combination.
JQ1 Potentiates the Effects of the ATR
Inhibitor (AZD6738) on the Apoptosis of
Leukemia Cells
Ataxia telangiectasia and Rad3 related (ATR) inhibitors have
been reported to display synergism with JQ1 in the induction of
apoptosis in lymphoma and melanoma cells (22, 23). Therefore,
we aimed to test and compare the effects of JQ1 combined with a
specific ATR inhibitor (AZD6738) or with azacitidine in leukemia
cells. The GI30 of AZD6738 was firstly calculated in HEL, U937,
and HL60 cell lines (Figure S1). Subsequently, these cell lines
were exposed to 1µM JQ1, 1µM azacitidine or the GI30 dose of
AZD6738 monotherapy or double combined treatment courses
(JQ1 + azacitidine, JQ1 + AZD8768, azacitidine + AZD6738)
for 48 h. In addition to U937 and HEL cells, a synergic effect of
JQ1 and azacitidine was observed in HL60 cells (Figures 5A–F).
In HL60 cells, the effects of JQ1 + AZD6738 were stronger than
JQ1 + azacitidine (Figure 5A), whereas JQ1 + azacitidine was
more potent in U937 cells (Figure 5C) and both combinations
produced similar effects in HEL cells (Figure 5E). AZA +
AZD6738 was also a promising combination, especially in
U937 cells (Figure 5B). pH2AX was induced by all treatment
schemes (monotherapy or combinations) in the three cell lines
(Figures 5G–I). Cleaved caspase-3 expression was consistent
with annexin V and cleaved PARP-1 results (Figures 5G–I).
DISCUSSION
Our results suggest that the short variant of BRD4 is a biological
determinant of MDS phenotype and aggressiveness, since the
two MDS subtypes (with lower and higher blast percentages)
and AML patients exhibited overexpression of BRD4S, but
particularly those with higher-risk disease. Moreover, a higher
expression of this gene predicted a worse overall outcome
in our cohort, in accordance with similar results for BRD4
overexpression and worse outcomes in solid tumors (24–26).
The overexpression of BRD4 isoforms in BA/F3 cells did
not induce IL-3 independence, suggesting that this gene it is
not and oncogene by itself. Moreover, in vitro studies showed
that BRD4 inhibition, combined with azacitidine or AZD6738,
synergistically induced apoptosis of leukemia cells.
Floyd et al. (13) described the BRD4 short isoform as an
endogenous inhibitor of DNA damage response since cell lines
with forced BRD4 hyper expression exhibited attenuated DNA
damage response signaling (13). In this context, we speculate
that the BRD4 short isoform could decrease the DNA damage
response, favoring the disease toward genetic instability and
clonal evolution. Our results using the BA/F3 cell model
indicate that BRD4 does not function as an oncogene when
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FIGURE 4 | BRD4 silencing increases apoptosis rate of U937 cells under
azacitidine treatment. (A) Efficacy of BRD4 silencing in U937 cells transduced
with lentivirus-mediated control (shControl) or BRD4 (shBRD4) measured by
RT-PCR. (B) Silenced and control cells were treated for 48 h with vehicle
(DMSO) or azacitidine (1 or 3µM): and apoptosis was detected by flow
cytometry. (C) Representative plot of increasing apoptosis of shBRD4 cells
under AZA treatment. Significant P-values (one-way Anova test) are indicated
in the graph. All bar graphs represent mean ± SD of at least four independent
experiments.
overexpressed alone, which is in accordance with previous studies
that have demonstrated that BET bromodomain proteins are not
oncogenes themselves, but may act as a coactivators or direct
modulators of other oncogenes, such as MYC and E2F proteins
(27, 28).
In accordance with experimental data from other cancers, our
data showed that BRD4 inhibition leads to variable apoptosis
induction. However, since BRD4 also causes an arrest in G0/G1,
and cells unable to differentiate undergo apoptosis, we cannot
affirm that BRD4 acts directly on apoptosis. Importantly, we
observed an additive effect of azacitidine combined with either
JQ1 treatment or BRD4 silencing. To our knowledge, this is
the first evidence for an additive effect between the standard
treatment for MDS and elderly AML (the hypomethylating agent
azacitidine) and a drug targeting an epigenetic modulator other
than histone deacetylase.
Interestingly, JQ1 treatment increased the levels of p-H2AX,
indicating a DDR pathway activation, even when using a lower
dose. Double strand-breaks (DSB) in damaged DNA cause the
phosphorylation of the neighboring histone H2AX at Ser139 via
ATM. The functional significance of p-H2AX is a signal that
facilitates DSB repair, presumably by causing the chromatin to be
more accessible for DNA repair. Once DNA repair fails, the cells
undergo death by activating apoptosis. Thus, apoptosis induction
following DNA damage is a protective mechanism that prevents
carcinogenesis (29). Some recent evidence suggests that DNA
methyltransferase 1 (DNMT1) inhibition could also activate
DDR, reinforcing the idea that epigenetic and genetic stability are
intrinsically linked to one another (30, 31). JQ1 is a Brodomain
and Extra-terminal (BET) inhibitor with activity blocking BRD4
(short and long isoforms), but also against other BET protein
members, such as BRD2, BRD3, and BRDT. Therefore, this non-
selective effect of JQ1 needs to be taken into consideration in the
interpretation of the data.
Despite not having yet been analyzed specifically in MDS
patients, there is increasing evidence supporting a role for BRD4
in AML pathogenesis and its potential therapeutic applicability.
Herrmann et al. (32) described the overexpression of BRD4 in
AML patient samples, even in highly enriched CD34+/CD38−
and CD34+/CD38+ stem and progenitor cells and showed that
JQ1 was capable of inducing the apoptosis of these cells. They
also demonstrated that JQ1 synergized with cytarabine, reducing
the cell viability of AML cells. Chen et al. (33) showed that BRD4
inhibition induced differentiation and death of IDH2 mutated
AML, whereas Dawson et al (34) reported a role for NPM1
mutation in the induction of a BRD4 transcriptional program
and that BET inhibition restored the NPM1 nuclear localization
and abrogated the BRD4-induced oncogenic transcriptional
program.
Stewart et al. (35) showed that JQ1 causes caspase
3/7-mediated apoptosis and a DNA damage response in
DNMT3a/NPM1-mutated AML, suggesting that JQ1 might
sensitize AML cells to p53-mediated cell death. Moreover,
recent data suggest a synergistic effect of the histone deacetylase
inhibitor, panobinostat, and JQ1 in AML cells (36). DDR
activation seems to function as a biomarker of BRD4 inhibition
efficacy, as cell lines presenting DDR activation also showed
apoptosis induction. Chen et al. (37) recently showed that
AZA-resistant MDS/AML cells have significantly increased
expressions of BRD4, BRD2, and DNMT1. However, many DNA
damage-induced cell death pathways are active in mammalian
cells and the involved mechanisms and protein networks are
complex and not fully understood (38). Therefore, our study
indicates (not confirm) that BRD4 inhibition induces apoptosis
through the activation of DDR.
Li et al. (39) recently demonstrated similar results regarding
the role of BRD4 in prostate cancer, where higher gene expression
was associated with worse outcomes and BRD4 inhibition
activated H2AX. The authors showed that BRD4 is essential
for the repair of DNA double-strand breaks (39). Muralidharan
et al showed a synergistic effect of BRD4 inhibition with
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FIGURE 5 | JQ1 effects on apoptosis of leukemia cell lines are increased with the ATR inhibitor AZD6738. Apoptosis rate and cell growth percentage in HL60 (A,B),
U937 (C,D), and HEL (E,F) leukemia cell lines treated with AZA, JQ1, or AZD6738 monotherapy or in double combinations in the indicated doses for 48 h. Protein
expression levels of pH2AX, cleaved caspase 3, and cleaved PARP-1 in HL60 (G), U937 (H), and HEL (I) leukemia cell lines treated with AZA, JQ1, or AZD6738
monotherapy or in double combinations in the indicated doses for 48 h. Actin (42 kDa) was used as a control for equal sample loading and the membrane was
developed with the ECL Western Blotting Analysis System. Densitometry was performed and the ratio of target proteins vs. actin compared with the normalized value
of control is shown. All bar graphs represent mean ± SD of at least four independent experiments. **P ≤ 0.01; ***P ≤ 0.001.
ATR inhibitors, inducing DDR in lymphoma cell lines (23), as
demonstrated here in leukemia cells.
Larger and different cohorts of patients are necessary to
confirm our results, since our cohort had low number of high-risk
cytogenetics patients. Our findings however are in accordance
with those from other authors supporting the existence of a
defective BRD4-dependent transcriptional program in MDS and
AML. The in vivo efficacy of JQ1 or other BET-targeting drugs
for MDS patients is currently unknown, even though preliminary
experimental and clinical data from BET inhibition in AML
patients showed that BET-targeting drugs presented low toxicity
profile and promising efficacy. Importantly, cord blood CD34
cells tolerated the effects of BRD4, with sustained cell viability
and lower apoptosis, suggesting that BRD4 has a different role
in normal vs. leukemic progenitor cells and, therefore, leukemic
cells could be more BRD4 dependent than normal progenitor
cells.
In conclusion, the BRD4 short variant is upregulated in
MDS and AML patients and functions as an independent MDS
prognostic factor, predicting worse outcomes. Our in vitro results
further demonstrated that BRD4 inhibition shows a synergism
with azacitidine or AZD6738, activating apoptosis, possibly
through DDR pathway activation.
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